Cleo Diagnostics Partners with Bio-Techne to Commercialise Ovarian Cancer Blood Test
Cleo Diagnostics Ltd (ASX: COV) has selected Bio-Techne’s Ella automated ELISA platform to support the delivery of its ovarian cancer blood test to market. The Ella system offers enhanced analytical sensitivity, improved precision, faster processing times, and reduced manual intervention compared with traditional ELISA methods. Cleo has already assessed the platform internally and confirmed its suitability for its proprietary biomarker panel and algorithm.
The company is progressing toward a binding agreement with Bio-Techne to begin analytical validation of its test kits. Once completed, the validated kits will be used to analyse approximately 500 blood samples collected in Cleo’s pivotal clinical trial. The resulting data will underpin the company’s planned 510(k) FDA submission. Following successful validation and regulatory steps, both parties intend to formalise a long-term commercial manufacturing supply agreement. Cleo’s patented CXCL10-based test aims to enable earlier and more accurate detection of ovarian cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Cleo Diagnostics Partners with Bio-Techne to Commercialise Ovarian Cancer Blood Test
Cleo Diagnostics Ltd (ASX: COV) has selected Bio-Techne’s Ella automated ELISA platform to support the delivery of its ovarian cancer blood test to market. The Ella system offers enhanced analytical sensitivity, improved precision, faster processing times, and reduced manual intervention compared with traditional ELISA methods. Cleo has already assessed the platform internally and confirmed its suitability for its proprietary biomarker panel and algorithm.
The company is progressing toward a binding agreement with Bio-Techne to begin analytical validation of its test kits. Once completed, the validated kits will be used to analyse approximately 500 blood samples collected in Cleo’s pivotal clinical trial. The resulting data will underpin the company’s planned 510(k) FDA submission. Following successful validation and regulatory steps, both parties intend to formalise a long-term commercial manufacturing supply agreement. Cleo’s patented CXCL10-based test aims to enable earlier and more accurate detection of ovarian cancer.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au